Cancer immunotherapies that target the immune checkpoints, such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD1 ligand-1 (PD-L1), have transformed the therapeutic landscape of a variety of malignancies1–3. This evidence concerns the gene CTLA4 and cancer.